ArticleBMC neurology2026
Prognostic value of the intracerebral hematoma volume-to-cerebrospinal fluid volume ratio in patients with spontaneous basal ganglia hemorrhage undergoing non-surgical treatment.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveThis study aims to evaluate the prognostic value of the ratio of intracerebral hematoma volume (IHV) to cerebrospinal fluid volume (CSFV) in patients with basal ganglia hemorrhage undergoing non-surgical treatment. By providing a quantitative reference for clinical decision-making, this research seeks to facilitate the early identification of patients with poor prognoses and to support the selection of optimal treatment strategies tailored to individual needs.
methodsThis retrospective study included patients with spontaneous basal ganglia hemorrhage who received non-surgical treatment at our hospital between January 2017 and October 2020. IHV, CSFV, and the maximum transverse diameter of the third ventricle (MTDTV) were measured, and baseline characteristics were collected. Prognosis was assessed at three months using the modified Rankin Scale (mRS), with scores ≤2 indicating good outcomes and scores ≥3 indicating poor outcomes. Correlations between clinical variables and prognosis were analyzed.
resultsA total of 125 patients were included in this study, among whom 74 (59.2%) experienced poor outcomes. Univariate analysis revealed significant differences in NIHSS score, GCS score, IHV, systolic blood pressure (SBP) and diastolic blood pressure (DBP) at admission, CSFV, IHV/CSFV, and MTDTV (P<0.05). Logistic regression analysis identified IHV/CSFV (OR=1.074, P=0.041) and SBP at admission (OR=1.052, P=0.005) as independent predictors of patient outcomes.IHV/CSFV demonstrated good discriminatory performance and may reflect the balance between hematoma burden and intracranial CSF reserve, potentially complementing established predictors. The area under the ROC curve for IHV/CSFV was 0.810 (95% CI: 0.733-0.887), with a cutoff value of 18.35% for predicting poor outcomes, yielding a sensitivity of 67.57% and specificity of 92.16%.
conclusionFor patients with spontaneous basal ganglia hemorrhage undergoing non-surgical treatment, admission SBP and the IHV/CSFV ratio were independently associated with poor prognosis in this cohort. As an exploratory composite imaging marker, IHV/CSFV was associated with outcome in our cohort and may represent a non-invasive, exploratory candidate marker for risk stratification that warrants further validation. Additionally, CSFV was significantly correlated with MTDTV, suggesting that CSFV could be effectively estimated through MTDTV measurements, a finding that could aid clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.